🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 2 of 15

  1. Escitalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mild-to-moderate Depression

    phase 3 small molecule completed

    1 trial

  2. Eslicarbazepine acetate (BIA 2-093)

    Bial Portela & Companhia S.A.

    Partial Epilepsy in Children and Adolescents

    phase 3 small molecule completed

    1 trial

  3. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  4. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  5. Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  6. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  7. Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. GA 20 mg/mL

    Teva Pharma GmbH

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  9. GV-971

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 3 small molecule on hold

    1 trial

  10. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    4 trials

  11. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    5 trials

  12. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    3 trials

  13. Gantenerumab

    Hoffmann-La Roche

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  14. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  15. Glatiramer Acetate (DB)

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  16. Glatiramer Acetate (GA) 40 mg

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  17. Glatiramer Acetate 20 mg/0.5 mL

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  18. Glatiramer acetate (GA)

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  19. H006629, H006629, H006629, LEVODOPA AND DECARBOXYLASE INHIBITOR , H006629

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

  20. Iclepertin

    Boehringer Ingelheim

    Schizophrenia

    phase 3 small molecule terminated

    2 trials

  21. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  22. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  23. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

  24. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial

  25. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  26. KW-6500

    KYOWA KIRIN AUSTRALIA PTY LTD

    Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  27. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  28. KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  29. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  30. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  31. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb Australia Pty Ltd

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  32. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule active

    1 trial

  33. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  34. Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  35. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  36. LB-102

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    4 trials

  37. LB-102 (50 mg tablet)

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  38. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial

  39. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  40. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  41. Laquinimod

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    3 trials

  42. Laquinimod

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  43. Laquinimod

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  44. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  45. Levetiracetam

    UCB Pharma

    Epilepsy

    phase 3 small molecule completed

    1 trial

  46. Levetiracetam NORMON 250 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 250 mg, Levetiracetam NORMON 500 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 500 mg

    The George Institute

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial

  47. Levetiracetam XR, Masked Keppra® placebo film-coated tablets (a placebo tablet inside a capsule), Keppra 500 mg film-coated tablets, Levetiracetam prolonged-release placebo granules

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial

  48. Levodopa-Carbidopa Intestinal Gel (LCIG)

    AbbVie

    Advanced Parkinson's Disease

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.